中国乳腺癌患者中 STAT3/p-STAT3 的临床病理和预后作用：一项荟萃分析。
Clinicopathological and Prognostic Role of STAT3/p-STAT3 in Breast Cancer Patients in China: A Meta-Analysis.
机构信息
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, P. R. China.
School of Pharmacy, Guangxi Medical University, Nanning, 530021, P. R. China.
出版信息
Sci Rep. 2019 Aug 2;9(1):11243. doi: 10.1038/s41598-019-47556-z.
In order to explore the important factors in the diagnosis of breast cancer in China, meta-analysis of previous studies was performed to understand the association between STAT3/p-STAT3 and breast cancer. Information about STAT3/p-STAT3 expression and clinical data about breast cancer in China in particular were gathered from PubMed, Web of Science, CNKI and WanFang databases. RevMan 5.3 and STATA 14.0 were used to analyze the occurrence, development and metastasis of breast cancer for 2818 patients in 18 studies. STAT3/p-STAT3 expression was higher in breast cancer tissue than in normal ones (OR = 7.48, 95% CI = 5.64-9.94), in highly differentiated breast cancer tissue than in lowly differentiated cancer tissues (OR = 2.13, 95% CI = 1.53-2.98), in III/IV stage breast cancer than in I/II stage breast cancer (OR = 3.58, 95% CI = 2.44-5.25), and in tissue with lymphatic metastasis than in normal tissues (OR = 3.72, 95% CI = 2.59-5.35), respectively. Thus, the expression of STAT3/p-STAT3 plays a clinicopathological and prognostic role in the diagnosis and treatment of Chinese breast cancer patients.
为了探讨中国乳腺癌诊断中的重要因素，对以往的研究进行了荟萃分析，以了解 STAT3/p-STAT3 与乳腺癌之间的关系。从 PubMed、Web of Science、CNKI 和万方数据库中收集了有关 STAT3/p-STAT3 表达和中国乳腺癌临床数据的信息。使用 RevMan 5.3 和 STATA 14.0 对 18 项研究中的 2818 名患者的乳腺癌发生、发展和转移情况进行了分析。乳腺癌组织中 STAT3/p-STAT3 的表达高于正常组织（OR=7.48，95%CI=5.64-9.94），高分化乳腺癌组织中 STAT3/p-STAT3 的表达高于低分化癌组织（OR=2.13，95%CI=1.53-2.98），III/IV 期乳腺癌组织中 STAT3/p-STAT3 的表达高于 I/II 期乳腺癌组织（OR=3.58，95%CI=2.44-5.25），有淋巴转移的组织中 STAT3/p-STAT3 的表达高于正常组织（OR=3.72，95%CI=2.59-5.35）。因此，STAT3/p-STAT3 的表达在中国乳腺癌患者的诊断和治疗中具有临床病理和预后作用。
Zotero 插件